Cargando…
Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
BACKGROUND: Delivering affordable cancer care is becoming increasingly important. Bevacizumab (BEV) is a costly molecular targeted agent effective for a variety of cancer including lung cancer. The objective of this review is to assess published economic evaluation of BEV in the treatment of non-sma...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411370/ https://www.ncbi.nlm.nih.gov/pubmed/22870040 http://dx.doi.org/10.2147/CEOR.S27770 |